Checkpoint Therapeutics, Inc. (CKPT) Can’t Be More Risky. The Stock Formed a Bearish Double Bottom Pattern

May 18, 2018 - By Vivian Currie

The chart of Checkpoint Therapeutics, Inc. (CKPT) shows a double bottom with $3.31 target or 9.00 % below today’s $3.64 share price. The 6 months chart pattern indicates high risk for the $116.54M company. It was reported on May, 18 by Finviz.com. If the $3.31 price target is reached, the company will be worth $10.49M less. Double bottoms are rare but powerful chart patterns.

The stock increased 2.10% or $0.08 during the last trading session, reaching $3.64. About 31,621 shares traded. Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) to report earnings on August, 8. They expect $-0.19 earnings per share, up 32.14 % or $0.09 from last year’s $-0.28 per share. After $-0.35 actual earnings per share reported by Checkpoint Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -45.71 % EPS growth.

Another recent and important Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) news was published by Nasdaq.com which published an article titled: “Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights” on May 10, 2018.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company has market cap of $116.54 million. The Company’s pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. It currently has negative earnings. The firm is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase.

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: